A trial of mass isoniazid preventive therapy for tuberculosis control

New England Journal of Medicine

Volumn 370, Issue 4, 2014, Pages 301-310

  Churchyard, Gavin J ^a,b,c   Fielding, Katherine L ^c   Lewis, James J ^c   Coetzee, Leonie ^a   Corbett, Elizabeth L ^c   Godfrey Faussett, Peter ^c   Hayes, Richard J ^c   Chaisson, Richard E ^d   Grant, Alison D ^c  

^a AURUM INSTITUTE   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892708174     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1214289     Document Type: Article

References (30)

1. Global tuberculosis report 2012. Geneva: World Health Organization, 2012 (WHO/HTM/TB/2012.6).
2. Chaisson RE, Martinson NA. Tuberculosis in Africa - combating an HIV-driven crisis. N Engl J Med 2008;358:1089-92.
3. Corbett EL, Churchyard GJ, Clayton TC, et al. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS 2000;14:2759-68.
4. Corbett EL, Churchyard GJ, Charalambos S, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002;34:1251-8.
5. Lewis JJ, Charalambous S, Day JH, et al. HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med 2009;180:1271-8.
6. van Halsema CL, Fielding KL, Chihota VN, Lewis JJ, Churchyard GJ, Grant AD. Trends in drug-resistant tuberculosis in a gold-mining workforce in South Africa, 2002-2008. Int J Tuberc Lung Dis 2012;16:967-73.
7. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012;9(7):e1001270.
8. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis 1979;119:827-30.
9. Comstock GW, Woolpert SF, Baum C. Isoniazid prophylaxis among Alaskan Eskimos: a progress report. Am Rev Respir Dis 1974;110:195-7.
10. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967;95:935-43.
11. Fielding KL, Grant AD, Hayes RJ, Chaisson RE, Corbett EL, Churchyard GJ. Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. Contemp Clin Trials 2011;32:382-92.
12. Grant AD, Coetzee L, Fielding KL, et al. 'Team up against TB': promoting involvement in Thibela TB, a trial of community-wide tuberculosis preventive therapy. AIDS 2010;24:Suppl 5:S37-S44.
13. Churchyard GJ, Fielding KL, Lewis JJ, Chihota VN, Hanifa Y, Grant AD. Symptom and chest radiographic screening for infectious tuberculosis prior to starting isoniazid preventive therapy: yield and proportion missed at screening. AIDS 2010; 24:Suppl 5:S19-S27.
14. Chihota VN, Grant AD, Fielding K, et al. Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. Int J Tuberc Lung Dis 2010;14:1024-31.
15. Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, Churchyard GJ. Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS 2010;24:Suppl 5:S29-S36.
16. Hanifa Y, Grant AD, Lewis J, Corbett EL, Fielding K, Churchyard G. Prevalence of latent tuberculosis infection among gold miners in South Africa. Int J Tuberc Lung Dis 2009;13:39-46.
17. Hayes RJ, Moulton LH. Cluster randomised trials. Boca Raton, FL: Chapman & Hall/CRC, 2009.
18. Horwitz O, Payne PG, Wilbek E. Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland. Bull World Health Organ 1966;35:509-26.
19. Nyboe J, Farah AR, Christensen OW. Report on tuberculosis chemotherapy pilot project (Tunisia 9). Geneva: World Health Organization, 1963.
20. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1970;26:28-106.
21. Samandari T, Agizew TB, Nyirenda S, et al. 6-Month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011;377:1588-98.
22. Leung CC, Rieder HL, Lange C, Yew WW. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J 2011;37:690-711.
23. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:Suppl 3: S221-S247.
24. Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, Godfrey-Faussett P. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001;15:215-22.
25. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001;15:2137-47.
26. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited healthcare resources. Lancet Infect Dis 2010;10:489-98.
27. Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, Dye C. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A 2010;107:19485-9.
28. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010;1:CD000171.
29. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365:11-20.
30. Grant AD, Charalambous S, Fielding KL, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005;293:2719-25.